Headlands Technologies LLC Raises Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Headlands Technologies LLC grew its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 196.7% during the fourth quarter, Holdings Channel reports. The institutional investor owned 89,314 shares of the company’s stock after buying an additional 59,211 shares during the period. Headlands Technologies LLC’s holdings in Recursion Pharmaceuticals were worth $604,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently made changes to their positions in RXRX. Intech Investment Management LLC bought a new position in shares of Recursion Pharmaceuticals in the third quarter worth about $349,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Recursion Pharmaceuticals by 17.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,940,680 shares of the company’s stock worth $12,789,000 after buying an additional 288,926 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Recursion Pharmaceuticals by 11.7% during the third quarter. The Manufacturers Life Insurance Company now owns 124,654 shares of the company’s stock worth $821,000 after acquiring an additional 13,041 shares during the last quarter. FMR LLC grew its stake in Recursion Pharmaceuticals by 2.1% during the third quarter. FMR LLC now owns 8,363,530 shares of the company’s stock valued at $55,116,000 after acquiring an additional 170,810 shares in the last quarter. Finally, MetLife Investment Management LLC lifted its stake in Recursion Pharmaceuticals by 13.7% in the 3rd quarter. MetLife Investment Management LLC now owns 136,541 shares of the company’s stock worth $900,000 after purchasing an additional 16,405 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Cowen reaffirmed a “hold” rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. KeyCorp decreased their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Needham & Company LLC reissued a “buy” rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Thursday, February 6th. Finally, Leerink Partners decreased their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a research note on Friday, February 28th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, Recursion Pharmaceuticals currently has an average rating of “Hold” and an average price target of $8.25.

Recursion Pharmaceuticals Stock Performance

NASDAQ RXRX opened at $5.29 on Thursday. The business’s 50 day moving average price is $7.34 and its 200-day moving average price is $6.98. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $4.93 and a fifty-two week high of $12.36. The company has a market cap of $2.13 billion, a P/E ratio of -3.46 and a beta of 0.85. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $4.60 million during the quarter, compared to analysts’ expectations of $19.04 million. During the same period in the prior year, the company posted ($0.42) EPS. The company’s revenue was down 57.8% compared to the same quarter last year. Sell-side analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.